Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis

Cardiovascular Drugs and Therapy

Volumn 12, Issue SUPPL. 1, 1998, Pages 111-118

  Jukema, J Wouter ^a   Van Boven, Ad J ^b   Zwinderman, Aeilko H ^c   Van Der Laarse, Arnaud ^a   Bruschke, Albert V G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Atherosclerosis; Calcium channel blockers; Lipids; Pravastatin

Indexed keywords

ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; PRAVASTATIN;

ANGIOCARDIOGRAPHY; ATHEROGENESIS; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; PRIORITY JOURNAL;

ANTICHOLESTEREMIC AGENTS; CALCIUM CHANNEL BLOCKERS; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; PRAVASTATIN;

EID: 0031956482     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1007733311487     Document Type: Article

References (46)

1. Buchwald H, Matts JP, Fitch LL, et al. for the Program on the Surgical Control of the Hyperlipidemias (POSCH) Group. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA 1992;268:1429-1433.
2. Waters D, Craven TE, Lespérance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 1993;87:1067-1075.
3. Azen SP, Mack WJ, Cashin-Hemphill L, et al. Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 1996;93:34-41.
4. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-3240.
5. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-1298.
6. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet or diet plus cholestyramine in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-569.
7. Waters D, Higginson L, Gladstone P, et al. the CCAIT Study Group. Effect of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-968.
8. MAAS investigators. Effect of simvastatin on coronary atheroma: The multicentre anti-atheroma study (MAAS). Lancet 1994;344:633-638.
9. Jukema JW, Bruschke AVG, van Boven AJ, et al. on behalf of the REGRESS study group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The "Regression Growth Evaluation Statin Study" (REGRESS). Circulation 1995;91: 2528-2540.
10. Bestehorn H-P, Rensing UFE, Roskamm H, et al. The effect of simvastatin on progression of coronary artery disease. The Multicenter Coronary Intervention Study (CIS). Eur Heart J 1997;18:226-234.
11. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-162.
12. Henry PD, Bentley KI. Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest 1981;68:1366-1369.
13. Strickberger SA, Russek LN, Phair RD. Evidence for increased aortic plasma membrane calcium transport caused by experimental atherosclerosis in rabbits. Circ Res 1988;62:75-80.
14. Kramsch DM, Aspen AJ, Rozler LJ. Atherosclerosis: Prevention by agents not affecting abnormal levels of blood lipids. Science 1981;213:1511-1512.
15. Loaldi A, Polese A, Montorsi P, et al. Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectoris. Am J Cardiol 1989;64:433-439.
16. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW, on behalf of the INTACT group investigators. Retardation of angiographie progression of coronary artery disease by nifedipine. Lancet 1990;335:1109-1113.
17. Waters D, Lespérance J, Francetich M, et al. A controlled clinical trial to assess the effect of calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990;82:1940-53.
18. Waters D, Lespérance J. Calcium channel blockers and coronary atherosclerosis: From the rabbit to the real world. Am Heart J 1994;128:1309-1316.
19. Jukema JW, Zwinderman AH, van Boven AJ, Reiber JHC, van der Laarse A, Lie KI, Bruschke AVG. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. Arterioscler Thromb Vase Biol 1996;16:425-430.
20. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-671.
21. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients hypercholesterolemia. Circulation 1994:89:2519-2524.
22. Lacoste L, Lam JYT, Hung J, Letchacovski, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995;92:3172-3177.
23. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-627.
24. Nayler WG. The antiatherogenic potential of the calcium antagonists, including amlodipine. In: Amlodipine. Berlin: Springer Verlag, 1993:178-198.
25. Mak T, Boehme P, Weglicki WB. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels. Circ Res 1992;70:1099-1103.
26. Nilsson J, Sjolund M, Palmberg L, von Euler AM, Jonzon B, Thyberg J. The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation. Atherosclerosis 1985; 58:109-122.
27. Betz E, Weiss HK, Heinle H, Fotev Z. Calcium antagonists and atherosclerosis. J Cardiovasc Pharmacol 1991;18 (Suppl. 10):S71-S75.
28. 2+ channel blockers modulate expression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density lipoprotein receptor genes stimulated by platelet-derived growth factor. Proc Natl Acad Sci USA 1991;88: 9041-9045.
29. Nomomoto A, Mutoh S, Hagihara H, Yamaguchi I. Smooth muscle cell migration induced by inflammatory cell products and its inhibition by a potent calcium antagonist, nilvadipine. Atherosclerosis 1988;72:213-219.
30. McMurray HF, Chahwala SB. Amlodipine exerts a potent antimigrational effect on aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 1992;20(Suppl. A):S54-S56.
31. Ware JA, Johnston PC, Smith M, Salzman EW. Inhibition of human platelet aggregation and cytoplasmic calcium responses by calcium antagonists. Studies with aequorin and quin-2. Circ Res 1986;59:39-42.
32. Hernandez R, Carvajal AR, Armas-de Hernandez MJ, Guerrero-Pajuelo J, Armas-Padilla MC, Barragan O, Machado-de Alvarado I. The effects of the calcium antagonist amlodipine on blood pressure and platelet aggregation in hypertensive patients. Postgrad Med J 1991;67(Suppl. 5):S38-S40.
33. Heider JG, Weinstein DB, Pickens C, Lan S, Su CM. Antiatherogenic activity of the calcium channel blockerisradipine (PN200-110): A novel effect on matrix synthesis independent of calcium channel blockade. Transplant Proc 1987;19(Suppl. 5):96-101.
34. Chichester CO, Rodgers RL. Effect of doxazosin on vascular collagen synthesis, arterial pressure and serum lipids in the spontaneously hypertensive rat. J Cardiovasc Pharmacol 1987;10(Suppl.):S21-S26.
35. Catapano AL. Calcium antagonists and atherosclerosis. Experimental evidence. Eur Heart J 1997(Suppl. A):A80-A86.
36. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of incident myocardial infarction associated with anti-hypertensive drug therapies. JAMA 1995;274:620-625.
37. Lenfant C. The calcium channel blocker scare. Lessons for the future. Circulation 1995;91:55-2856.
38. HINT research group. Early treatment of unstable angina in the coronary care unit: A randomised, double blind, placebo controlled comparison of recurrent ischaemia in patients with nifedipine or metoprolol or both. Br Heart J 1986;56:400-413.
39. The Israeli Sprint Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 1988;9:354-364.
40. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-392.
41. Gibson RS, Boden WE, Theroux P, et al. and the Diltiazem Reinfarction Group. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. N Engl J Med 1986;315:423-429.
42. Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol vs. verapamil in patients with stable angina pectoris. The Angina Prognosis Study In Stockholm (APSIS). Eur Heart J 1996;17:76-81.
43. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-1114.
44. Etingin OR, Hajjar DP. Calcium channel blockers enhance cholesteryl ester hydrolysis and decrease total accumulation in human aortic tissue. Circ Res 1990;66:185-190.
45. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994;344:793-795.
46. Mak IT, Weglicki WB. Comparative antioxidant activities of propanolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation. Circ Res 1990;66: 1449-1452.